279 related articles for article (PubMed ID: 28355368)
1. Treatment of benign prostatic hyperplasia.
Nunes RV; Manzano J; Truzzi JC; Nardi A; Silvinato A; Bernardo WM;
Rev Assoc Med Bras (1992); 2017 Feb; 63(2):95-99. PubMed ID: 28355368
[No Abstract] [Full Text] [Related]
2. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
Sarma AV; Wei JT
N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
[No Abstract] [Full Text] [Related]
3. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
4. α-Blockers, 5-α-Reductase Inhibitors, Acetylcholine, β3 Agonists, and Phosphodiesterase-5s in Medical Management of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: How Much Do the Different Formulations Actually Matter in the Classes?
Chughtai B; Thomas D; Kaplan S
Urol Clin North Am; 2016 Aug; 43(3):351-6. PubMed ID: 27476127
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for non-neurogenic male lower urinary tract symptoms: 1 + 1 does not equal 2.
Lepor H
Eur Urol; 2013 Aug; 64(2):244-6; discussion 246-7. PubMed ID: 23473577
[No Abstract] [Full Text] [Related]
6. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Schauer I; Madersbacher S
Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
[TBL] [Abstract][Full Text] [Related]
7. Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm.
Osman NI; Aldamanhori R; Mangera A; Chapple CR
Urol Clin North Am; 2016 Aug; 43(3):337-49. PubMed ID: 27476126
[TBL] [Abstract][Full Text] [Related]
8. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
9. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
10. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
11. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
[TBL] [Abstract][Full Text] [Related]
12. Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.
Marberger M
Adv Ther; 2013 Apr; 30(4):309-19. PubMed ID: 23584673
[TBL] [Abstract][Full Text] [Related]
13. The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.
Rosenberg MT; Staskin D; Riley J; Sant G; Miner M
Curr Urol Rep; 2013 Dec; 14(6):595-605. PubMed ID: 24026361
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
[TBL] [Abstract][Full Text] [Related]
15. Early Surgical Intervention is Beneficial in Avoiding Complications in Patients with Male Lower Urinary Tract Symptoms.
Bachmann A; Rapoport LM; Wetterauer C
Eur Urol Focus; 2018 Jan; 4(1):2-3. PubMed ID: 29680700
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Martinelli E
Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
[TBL] [Abstract][Full Text] [Related]
18. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. Letter.
Tutolo M; Briganti A; Salonia A; Montorsi F
J Urol; 2023 Jul; 210(1):33-34. PubMed ID: 37053542
[No Abstract] [Full Text] [Related]
19. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. Reply.
Lenfant L; Pinar U; Roupret M; Mozer P; Chartier-Kastler E; Seisen T
J Urol; 2023 Jul; 210(1):34-35. PubMed ID: 37053541
[No Abstract] [Full Text] [Related]
20. Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study.
Gravas S
Eur Urol; 2015 Aug; 68(2):338-9. PubMed ID: 26149729
[No Abstract] [Full Text] [Related]
[Next] [New Search]
